Sign In
Buy VRCA
$5.22
-0.0400 (-0.760%)
At Close: Jul 31, 2026
First Look: CME outage, Black Friday shifts, AI job impact
08:21am, Friday, 28'th Nov 2025
Stock News CME restores trading after data center cooling failure: CME Group (CME) halted Globex futures and options overnight due to a cooling issue at a Cyrus
Market Today: Stocks Rally, Tesla Robotaxi and Nvidia Scrutiny
05:35pm, Wednesday, 26'th Nov 2025
Stock News Campbell's exec ousted after viral recording: Campbell Soup (CPB) said it terminated IT VP Martin Bally after an internal review concluded he was the
First Look: Campbell Soup fallout, Alphabet AI strength, Nvidia rebuttal
07:39am, Wednesday, 26'th Nov 2025
Stock News Campbell puts exec on leave: Campbell's Co. (CPB) sidelined a senior IT executive after a lawsuit and leaked audio alleged he disparaged customers an
Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway
08:00am, Monday, 24'th Nov 2025
Proceeds will fully retire debt facility from OrbiMed and fund company operations, thereby extending expected cash runway into mid-2027 Financing anchored by Caligan Partners LP and PBM Capital, along
Verrica Pharmaceuticals Inc. (VRCA) Q3 2025 Earnings Call Transcript
10:37am, Monday, 17'th Nov 2025
Verrica Pharmaceuticals Inc. ( VRCA ) Q3 2025 Earnings Call November 17, 2025 8:30 AM EST Company Participants Jayson Rieger - President, CEO & Director John Kirby - Interim Chief Financial Officer Co
Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results
04:05pm, Friday, 14'th Nov 2025
– Company reports $14.3 million in revenue in Q3'25, consisting of $3.6 million in YCANTH ® revenue and $10.7 million of license and collaboration revenue –
– Exploratory Phase 2 analysis shows Verrica's novel oncolytic peptide, VP-315, reprograms the tumor microenvironment, increasing cytotoxic T-cell infiltration and reducing immunosuppressive T-regul
Halper Sadeh LLC Encourages Verrica Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights
11:00am, Friday, 24'th Oct 2025
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Verrica Pharmaceuticals, Inc. (NASDAQ: VRCA) breached their fiducia
– EMA concludes that the primary endpoint and supportive secondary endpoints from prior successful Phase 3 studies conducted in the U.S. and Japan are adequate to support a filing for the approval o
WEST CHESTER, Pa., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin disease
– Approval triggers $10 million cash milestone payment to Verrica – – YCANTH ® approval in Japan addresses significant unmet need of patients with molluscum – – Verrica maintains ownership
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
07:00am, Tuesday, 02'nd Sep 2025
WEST CHESTER, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseas
Verrica Pharmaceuticals Inc. (VRCA) Q2 2025 Earnings Call Transcript
09:20pm, Tuesday, 12'th Aug 2025
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Jayson M. Rieger - President, CEO & Director John J.
Verrica Pharmaceuticals Inc. (VRCA) Q2 Earnings and Revenues Beat Estimates
06:21pm, Tuesday, 12'th Aug 2025
Verrica Pharmaceuticals Inc. (VRCA) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.7 per share. This compares to a loss of $3.1 per share a y
Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results
04:01pm, Tuesday, 12'th Aug 2025
– Company reports $12.7 million in revenue in Q2'25, consisting primarily of $4.5 million in YCANTH ® revenue, net, reflecting sequential growth of 32.5% over Q1'25 and $8.0 million in mileston
